DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg
A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Doravirine/Islatravir (100 mg/0.25 mg) in Pediatric Participants With HIV-1 Infection Who Are Virologically Suppressed or Treatment-Naïve, Are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg
This is a phase 2 study of the pharmacokinetics, safety, and efficacy of oral doravirine/islatravir (100 mg/0.25 mg) [MK-8591A] in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection who are virologically suppressed or treatment-naive.
The Base Study will last from Day 1 to Week 96. At Week 96, participants will be given the option to participate in an optional Study Extension and receive DOR/ISL until Week 240 or until it becomes commercially accessible, whichever is first.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Toll Free Number
- 電話番号:1-888-577-8839
- メール:Trialsites@merck.com
研究場所
-
-
Florida
-
Tampa、Florida、アメリカ、33612
- University of South Florida ( Site 1505)
-
コンタクト:
- Study Coordinator
- 電話番号:813-821-8039
-
-
New York
-
The Bronx、New York、アメリカ、10467
- The Children's Hospital at Montefiore ( Site 1507)
-
コンタクト:
- Study Coordinator
- 電話番号:718-741-2497
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Pediatric participant with HIV-1 <18 years of age
- Body weight ≥35 kg
- Is TN (HIV-1 positive with plasma HIV-1 RNA ≥500 copies/mL) or VS (HIV-1 positive at screening with plasma HIV-1 RNA <50 copies/mL AND has received stable, continuous 2- or 3-drug antiretroviral therapy (ART) for ≥3 months prior to providing informed consent)
Exclusion Criteria:
- HIV-2 infection
- Hypsensitivity/contraindication to any components of study medication or as determined by the investigator
- Has an active diagnosis of hepatitis due to any cause
- history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma
- Has a history or current evidence of any condition (including active tuberculosis infection, COVID-19, or other infections), therapy, laboratory abnormality, or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study
- Is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or any prohibited therapies
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:DOR/ISL
Participants receive DOR/ISL 100 mg/0.25 mg once daily (qd) for 96 weeks. Participants will have the option to participate in the Study Extension and receive DOR/ISL until Week 240 or it becomes commercially available, whichever is first. |
DOR/ISL 100 mg/0.25 mg tablet taken by mouth qd
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Area under the plasma conentration-time curve from dosing to 24 hours postdose (AUC0-24) of ISL
時間枠:At designated timepoints on Day 28
|
The plasma AUC0-24 will be assessed. |
At designated timepoints on Day 28
|
|
Maximum plasma concentration (Cmax) of ISL
時間枠:At designated timepoints on Day 28
|
The plasma Cmax will be assessed. |
At designated timepoints on Day 28
|
|
Time to maximum plasma concentration (Tmax) of ISL
時間枠:At designated timepoints on Day 28
|
The plasma Tmax will be assessed. |
At designated timepoints on Day 28
|
|
Apparent plasma terminal half-life (t½) of ISL
時間枠:At designated timepoints on Day 28
|
The plasma t½ will be assessed. |
At designated timepoints on Day 28
|
|
Apparent clearance (CL/F) of ISL
時間枠:At designated timepoints on Day 28
|
The CL/F will be assessed. |
At designated timepoints on Day 28
|
|
Volume of distribution (Vz/F) of ISL
時間枠:At designated timepoints on Day 28
|
The Vz/F will be assessed. |
At designated timepoints on Day 28
|
|
Percentage of participants with ≥1 adverse event (AE) through Week 24
時間枠:Up to ~24 weeks
|
The percentage of participants with AE(s) will be assessed. |
Up to ~24 weeks
|
|
Percentage of participants discontinuing from study therapy due to AE(s) through Week 24
時間枠:Up to ~24 weeks
|
The percentage of participants discontinuing from therapy due to AE(s) will be assessed. |
Up to ~24 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of participants with ≥1 AE through Week 96
時間枠:Up to 96 weeks
|
The percentage of participants with AE(s) will be assessed. |
Up to 96 weeks
|
|
Percentage of participants discontinuing from study therapy due to AE(s) through Week 96
時間枠:Up to 96 weeks
|
The percentage of participants with AE(s) will be assessed. |
Up to 96 weeks
|
|
Percentage of virologically-suppressed (VS) participants with Human Immunodeficiency Virus Type 1 (HIV-1) ribonucleic acid (RNA) ≥50 copies/mL
時間枠:Weeks 24, 48, and 96
|
The percentage of VS participants with HIV-1 RNA ≥50 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of VS participants with HIV-1 RNA <50 copies/mL
時間枠:Weeks 24, 48, and 96
|
The percentage of VS participants with HIV-1 RNA <50 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of VS participants with HIV-1 RNA <200 copies/mL
時間枠:Weeks 24, 48, and 96
|
The percentage of VS participants with HIV-1 RNA <200 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of treatment-naive (TN) participants with HIV-1 RNA <50 copies/mL
時間枠:Weeks 24, 48, and 96
|
The percentage of TN participants with HIV-1 RNA <50 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of TN participants with HIV-1 RNA <200 copies/mL
時間枠:Weeks 24, 48, and 96
|
The percentage of TN participants with HIV-1 RNA <200 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Change from baseline in CD4+ T-cell counts in VS and TN participants
時間枠:Weeks 24, 48, and 96
|
The change from baseline in CD4+ T-cell counts will be assessed in VS and TN participants. |
Weeks 24, 48, and 96
|
|
Percentage of participants with viral drug resistance to DOR or ISL
時間枠:Weeks 24, 48, 96, and 144
|
The percentage of participants with viral resistance-associated substitutions will be assessed during Weeks 24, 48, 96, and 144. |
Weeks 24, 48, 96, and 144
|
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 8591A-063
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。